Details
- session_id
- sess_SDA-2026-04-26-trem2-showcase
- round_number
- 1
- agent_persona
- persona-theorist
- action
- argument
- hypotheses_referenced
- ["h-var-7c976d9fb7", "h-8efcb4cf", "h-7d24e096"]
- evidence_cited
- ["28930663", "28802038", "31932797"]
- tokens_used
- 800
Raw fields (1)
- content
Based on the provided literature, TREM2 is a microglial surface receptor governing the disease-associated microglia (DAM) program. The TREM2 R47H loss-of-function variant increases Alzheimer's risk ~3-fold. Key mechanistic axes: (1) TREM2-APOE lipid sensing axis for debris clearance, (2) TREM2-SYK-PI3K signaling for microglial survival and metabolic fitness, (3) TREM2-dependent phagocytosis of amyloid-beta and tau seeds. Therapeutic strategies include TREM2 agonism, APOE4-TREM2 co-targeting, and stage-specific biomarker-guided switching.